Annals of Military and Health Sciences Research

Published by: Kowsar

Serum Lysophosphatidic Acid Level in Chronic Myeloid Leukemia

Beheshteh Abouhamzeh 1 , Iraj Mirzaii-Dizgah 2 , * and Amin Ravaei 1
Authors Information
1 Department of Anatomy, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
2 Department of Physiology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
Article information
  • Annals of Military and Health Sciences Research: March 2017, 15 (1); e62801
  • Published Online: March 31, 2017
  • Article Type: Original Article
  • Received: December 31, 2016
  • Revised: January 31, 2017
  • Accepted: March 3, 2017
  • DOI: 10.5812/amh.62801

To Cite: Abouhamzeh B, Mirzaii-Dizgah I, Ravaei A. Serum Lysophosphatidic Acid Level in Chronic Myeloid Leukemia, Ann Mil Health Sci Res. 2017 ; 15(1):e62801. doi: 10.5812/amh.62801.

Copyright © 2017, Annals of Military and Health Sciences Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Lee SJ. Chronic myelogenous leukaemia. Br J Haematol. 2000; 111(4): 993-1009[PubMed]
  • 2. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem. 2004; 279(10): 9653-61[DOI][PubMed]
  • 3. Lee J, Park SY, Lee EK, Park CG, Chung HC, Rha SY, et al. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression. Clin Cancer Res. 2006; 12(21): 6351-8[DOI][PubMed]
  • 4. Rusovici R, Ghaleb A, Shim H, Yang VW, Yun CC. Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad. Biochim Biophys Acta. 2007; 1770(8): 1194-203[DOI][PubMed]
  • 5. Meleh M, Pozlep B, Mlakar A, Meden-Vrtovec H, Zupancic-Kralj L. Determination of serum lysophosphatidic acid as a potential biomarker for ovarian cancer. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 858(1-2): 287-91[DOI][PubMed]
  • 6. Ortlepp C, Steudel C, Heiderich C, Koch S, Jacobi A, Ryser M, et al. Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation. Exp Hematol. 2013; 41(5): 444-61[DOI][PubMed]
  • 7. Fearon KC, Voss AC, Hustead DS, Cancer Cachexia Study G. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006; 83(6): 1345-50[PubMed]
  • 8. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients, Eastern cooperative oncology group. Am J Med. 1980; 69(4): 491-7[DOI]
  • 9. Ruiz Garcla V, Juan O, Perez Hoyos S, Peiro R, Ramon N, Rosero MA, et al. Megestrol acetate, a systematic review usefulness about the weight gain in neoplastic patients with cachexia. Med Clin. 2002; 119(5): 166-70[DOI][PubMed]
  • 10. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004; 89(6): 2832-6[DOI][PubMed]
  • 11. Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer. 2010; 102(6): 941-6[DOI][PubMed]
  • 12. Li YY, Zhang WC, Zhang JL, Zheng CJ, Zhu H, Yu HM, et al. Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis. Lipids Health Dis. 2015; 14: 72[DOI][PubMed]
  • 13. Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J, et al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009; 69(13): 5441-9[DOI][PubMed]
  • 14. Yoon HR, Kim H, Cho SH. Quantitative analysis of acyl lysophosphatidic acid in plasma using negative ionization tandem mass spectrometry. J Chromatogr B. 2003; 788(1): 85-92[DOI][PubMed]
  • 15. Meng Y, Kang S, So J, Reierstad S, Fishman DA. Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis. Gynecol Oncol. 2005; 96(2): 462-9[DOI][PubMed]
  • 16. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, et al. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res. 2006; 66(5): 2740-8[DOI][PubMed]
  • 17. Oyesanya RA, Lee ZP, Wu J, Chen J, Song Y, Mukherjee A, et al. Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells. FASEB J. 2008; 22(8): 2639-51[DOI][PubMed]
  • 18. Hu X, Mendoza FJ, Sun J, Banerji V, Johnston JB, Gibson SB. Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. Cell Signal. 2008; 20(6): 1198-208[DOI][PubMed]
  • 19. Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA, et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res. 1999; 5(11): 3704-10[PubMed]
  • 20. Underiner TL, Ruggeri B, Gingrich DE. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem. 2004; 11(6): 731-45[PubMed]
  • 21. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer. Am J Pathol. 1998; 153(4): 1249-56[DOI][PubMed]
  • 22. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res. 1995; 1(10): 1223-32[PubMed]
  • 23. Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, Belinson J, et al. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res. 2006; 66(16): 7983-90[DOI][PubMed]
  • 24. Do TV, Symowicz JC, Berman DM, Liotta LA, Petricoin E3, Stack MS, et al. Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. Mol Cancer Res. 2007; 5(2): 121-31[DOI][PubMed]
  • 25. Bian D, Su S, Mahanivong C, Cheng RK, Han Q, Pan ZK, et al. Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway. Cancer Res. 2004; 64(12): 4209-17[DOI][PubMed]
  • 26. Kim MH, Park JS, Chang HJ, Baek MK, Kim HR, Shin BA, et al. Lysophosphatidic acid promotes cell invasion by up-regulating the urokinase-type plasminogen activator receptor in human gastric cancer cells. J Cell Biochem. 2008; 104(3): 1102-12[DOI][PubMed]
  • 27. Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta. 2008; 1781(9): 513-8[DOI][PubMed]
  • 28. Pages C, Simon MF, Valet P, Saulnier Blache JS. Lysophosphatidic acid synthesis and release . Prostaglandins Other Lipid Mediat. 2001; 64(1-4): 1-10[DOI][PubMed]
  • 29. Hecht JH, Weiner JA, Post SR, Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol. 1996; 135(4): 1071-83[PubMed]
  • 30. Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, et al. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem. 2006; 281(35): 25822-30[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments